marrow

@MaverickNY No you are not the only one who hates black backgrounded slides.

RT @BldCancerDoc: Honored to serve #BMT colleagues and @ASBMT 🙏 https://t.co/8UwhYxnXRc

RT @Mohty_EBMT: Getting ready for the last day of #EBMT17 https://t.co/mSXYXjSFLi

Have to leave Marseille and #ebmt2017 now. Thanks to all #bmtsm people and others for an enjoyable and productive time inc #WMDA and #WBMT.

RT @BldCancerDoc: #EBMT17 @KoontzOncology 👇 https://t.co/ExNRAu8WEh

RT @drjgauthier: #EBMT17 Giannoni L. Higher number of HLA mismatches does not impact outcome using the PT Cy platform #bmtsm #EBMTYA https:…

Rainer Storb presenting 60 years of HSCT at #EBMT17 https://t.co/LDkXN4Ru5D

@sharonsschwarz Ta.

RT @drng: Ping @marrow https://t.co/qoUtjJXnMV

Unless you consider PNH a thrombophilia https://t.co/4IAwYCNTAL

@thelimbichaem I wish I knew.

Bad news. Available clinical trial? https://t.co/BAvgCaTkDf

RT @OncologyAdvance: Meet the editor of our new resource centre @marrow #haematology at Royal Melbourne Hospital https://t.co/iiCsC3VyvT ht…

RT @timfenske: Dr Fred Appelbaum presenting on recent advances in allo-HCT at our annual Heme Malig Symposium. https://t.co/0mcPQzO4ju

RT @MedicalAbacus: Acquired Resistance in WM Patients on #Ibrutinib #imw2017 #hematology #oncology #cancer https://t.co/xKnuLXjYH1

Site initiation for REACH2 Study of ruxolitinib in refractory acute #GVHD at @TheRMH today. #bmtsm

Syrians Seek Care Abroad https://t.co/kscWq0ff8b

RT @ElsevierAUS: Research Brings Hope - New Rare #Haematology Resource Centre for HCPs launched today #RareDiseaseDay #HSANZ https://t.co/e…

RT @POASBMT: Mary Horowitz @CIBMTR recognizing spectacular efforts of #BMTTandem17 co-chair @davidmarks1958. Thanks also from @ASBMT! @DrMv…

Kochenderfer presenting his results of anti CD19 CAR T cells for lymphoma including after allo. Significant CR rate… https://t.co/r1zMsPL49Y

@DrPaulyDeSantis I suspect you're talking about Saad S Kenderian who presented the ruxolitinib paper.

RT @hemedoc: #BMTTandem17 Schmid: prophylactic DLI beneficial for high-risk AML but not low/intermediate-risk https://t.co/y4Yo9pupHm

RT @hemedoc: #BMTTandem17 Walston: Inflammatory response activated in frail elderly and "doesn't turn off" https://t.co/p7PxNbmZSS

Avigan leading a CTN study with vaccine in MM post auto. #BMTTandem17 https://t.co/0JXsPekddl

RT @CIBMTR: Safe travels to #BMTTandem17. We will see you in the sunshine state – Orlando, Florida! Reminder registration check-in opens to…